TherapeuticsMD Inc (TXMD) Releases Earnings Results, Misses Expectations By $-0.02 EPS

TherapeuticsMD Inc (TXMD) reported quarterly earnings results on Tuesday, May-3-2016. The company reported $-0.11 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.09. The company posted revenue of $4.90 million in the period, compared to analysts expectations of $5.75 million. The company’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.13 EPS.

Many Wall Street Analysts have commented on TherapeuticsMD Inc. Goldman Initiated TherapeuticsMD Inc on Apr 4, 2016 to “Buy”, Price Target of the shares are set at $10.

TherapeuticsMD Inc opened for trading at $8.32 and hit $8.41 on the upside on Monday, eventually ending the session at $8.41, with a gain of 1.94% or 0.16 points. The heightened volatility saw the trading volume jump to 8,15,902 shares. Company has a market cap of $1,650 M.

In a different news, on Mar 14, 2016, Cooper C. Collins (director) purchased 16,000 shares at $6.23 per share price. According to the SEC, on Aug 27, 2015, Angus C. Russell (director) purchased 13,500 shares at $5.98 per share price. On Aug 24, 2015, Tommy G Thompson (director) purchased 10,798 shares at $6.29 per share price, according to the Form-4 filing with the securities and exchange commission.

TherapeuticsMD Inc. is a women’s health care product company. The Company is engaged in creating and commercializing products for women. The Company is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. It manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter (OTC) vitamins. It markets its prescription and OTC prenatal vitamins and other products under its vitaMedMD brand name and duplicate formulations of its prescription prenatal vitamin products also referred to as generic formulations under its BocaGreenMD brand name. The Company’s products include prenatal vitamins vitaMedMD Plus Rx vitaMedMD One Rx vitaMedMD RediChew Rx and BocaGreenMD Prena1 line of prescription prenatal vitamins which included three prescription prenatal vitamins that were generic formulations of its vitaMedMD-branded prescription prenatal vitamins.

TherapeuticsMD Inc

Leave a Reply

TherapeuticsMD Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on TherapeuticsMD Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.